---
title: "Verastem (VSTM) news: offering"
url: "https://aibio.space/companies/verastem/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "VSTM offering news: Verastem agrees to $75 million private placement of stock and pre-funded warrants. Verastem, Inc. (NASDAQ: VSTM), United States."
---

VSTM Verastem, Inc. NASDAQ · United States

# Verastem (VSTM) news VSTM offering news

Financings · 2025-04-25

## [Verastem agrees to $75 million private placement of stock and pre-funded warrants](https://aibio.space/news/verastem-agrees-75-million-private-placement-stock-pre-funded-warrants/)

Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.

## Latest Verastem news

1. 2025-04-25 Financings [Verastem Oncology announces $75 million private placement led by RTW](https://aibio.space/news/verastem-oncology-announces-75-million-private-placement-led-rtw/) Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
2. 2025-01-13 Debt Financing [Verastem sells $75.0 million of notes to Oberland Capital and repays Oxford loan](https://aibio.space/news/verastem-sells-75-0-million-notes-oberland-capital-repays-oxford-loan/) The note purchase agreement allows up to $150.0 million of notes with interest capped at 9.75%. Verastem also sold 1,416,939 shares to Oberland funds at $5.2931 per share and received about $32.3 million in net proceeds from the notes after the Oxford payoff. Its year-end cash figure is unaudited and preliminary.

## Verastem at a glance

- **Ticker**: VSTM

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $136.4 million

### Related companies

- [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) NASDAQ: RAPP
- [Aditxt](https://aibio.space/companies/aditxt/) OTC: ADTX
- [Climb Bio](https://aibio.space/companies/climb-bio/) NASDAQ: CLYM
- [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY
- [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW
- [FibroBiologics](https://aibio.space/companies/fibrobiologics/) NASDAQ: FBLG
- [Enzolytics](https://aibio.space/companies/enzolytics/) OTC: ENZC
- [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) NASDAQ: KRYS

### Also on NASDAQ

- [TELA Bio](https://aibio.space/companies/tela-bio/) TELA
- [Propanc Biopharma](https://aibio.space/companies/propanc-biopharma/) PPCB
- [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) DMAC
- [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX
- [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) APRE
- [Universe Pharmaceuticals](https://aibio.space/companies/universe-pharmaceuticals/) UPC

## Verastem annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$30.9 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) |
| Research and development | [$114.6 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) | [$81.3 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) |
| Net income (loss) | [-$209.5 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) | [-$130.6 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) |
| Cash from operations | [-$137.5 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) | [-$104.8 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) |
| Cash and equivalents | [$205.0 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092007/) | [$88.8 million](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $136.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Verastem

Has Verastem raised money recently?

Our latest story on this, dated Apr 25, 2025: "Verastem agrees to $75 million private placement of stock and pre-funded warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/verastem-agrees-75-million-private-placement-stock-pre-funded-warrants/).

What is the ticker symbol of Verastem?

Verastem, Inc. trades under the ticker VSTM on NASDAQ.

Where is Verastem listed?

Verastem, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2VSA; LS:A3EHM3; LSE:0LOV; LSX:A3EHM3.

What is the SEC CIK of Verastem?

The SEC Central Index Key (CIK) for Verastem, Inc. is 1526119. Its filings are on SEC EDGAR.

How many shares does Verastem have outstanding?

90,563,441 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.

Which country or territory is Verastem listed under?

Our directory records Verastem, Inc. under United States.

What does Verastem do?

Our directory classifies Verastem, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Verastem?

The ISIN recorded for Verastem, Inc. is US92337C2035.

Does aibio.space cover Verastem?

aibio.space lists Verastem, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Verastem incorporated?

SEC records list its state or country of incorporation as MA.

What was Verastem's revenue last year?

$30.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Verastem profitable?

Verastem, Inc. reported a net loss of $209.5 million for the fiscal year ended Dec 31, 2025, and used $137.5 million of cash in operations, per its annual report to the SEC.

How much does Verastem spend on research and development?

$114.6 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Verastem have?

$136.4 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Verastem (VSTM) stock news?

Our latest story on Verastem, dated Apr 25, 2025: "Verastem agrees to $75 million private placement of stock and pre-funded warrants". Verastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock. [Source](https://aibio.space/news/verastem-agrees-75-million-private-placement-stock-pre-funded-warrants/).

## Investor discussion: Verastem

Members talk about Verastem (VSTM). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Verastem, newest first. Each line links the filing it comes from.

1. 2026-08-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_ex99-1.htm)
2. 2026-06-23 Financings Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_ex99-1.htm)
3. 2026-05-07 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465926057126/tm2613842d1_ex99-1.htm)
4. 2026-03-04 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023462/tm267866d1_ex99-1.htm)
5. 2026-01-08 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/tm262531d1_ex99-1.htm)
6. 2025-11-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465925111326/tm2529742-1_424b5.htm)
7. 2025-08-08 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465925075498/tm2522593-1_s3.htm)
8. 2025-05-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465925047877/tm2514911-1_s3.htm)
9. 2025-04-25 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/tm2513177d1_ex99-1.htm)
10. 2025-01-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1526119/000110465925002859/tm253090d1_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VSTM on TradingView](https://www.tradingview.com/symbols/NASDAQ-VSTM/).

## SEC filings and registration

- **SEC name**: Verastem, Inc.

- **CIK**: 1526119

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: VSTM (Nasdaq)

- **State or country of incorporation**: MA

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 117 KENDRICK STREET, NEEDHAM, MA, 02494

- **Phone**: (781) 292-4200

- **Shares outstanding**: 90,563,441 as of 2026-08-03 (10-Q filed 2026-08-06)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115880/tm2627537d6_8k.htm) filed 2026-10-14
- [424B5](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115879/tm2627537-5_424b5.htm) filed 2026-10-14
- [424B5](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115875/tm2627537-1_424b5.htm) filed 2026-10-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_8k.htm) filed 2026-10-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_8k.htm) filed 2026-08-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_8k.htm) filed 2026-08-06
- [10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092007/vstm-20260630x10q.htm) filed 2026-08-06
- [8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm) filed 2026-06-23

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001526119), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Verastem, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VSTM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Verastem, Inc.

- **Ticker**: VSTM

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US92337C2035

- **Other listed symbols**: GETTEX:2VSA; LS:A3EHM3; LSE:0LOV; LSX:A3EHM3

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VSTM/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/verastem/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Verastem (VSTM) news: offering", 2026-10-31, https://aibio.space/companies/verastem/